Stimulation of glucose transport in osteoblastic cells by parathyroid hormone and insulin-like growth factor I by Zoidis, E. et al.
Stimulation of glucose transport in osteoblastic cells
by parathyroid hormone and insulin-like growth factor I
E. Zoidis • C. Ghirlanda-Keller • C. Schmid
Received: 10 May 2010 / Accepted: 28 October 2010 / Published online: 13 November 2010
 Springer Science+Business Media, LLC. 2010
Abstract Insulin and parathyroid hormone (PTH) regu-
late glucose metabolism in bone cells. In order to differ-
entiate between the effects of these hormones and to
compare the potency of insulin with that of insulin-like
growth factor (IGF) I, we treated rat bone-derived osteo-
blastic (PyMS) cells for different time periods and at dif-
ferent concentrations with insulin, IGF I, or PTH, and
measured [1-14C]-2-deoxy-D-glucose (2DG) uptake and
incorporation of D-[U-14C] glucose into glycogen. 2DG
uptake was Na-independent with an apparent affinity con-
stant (KM) of *2 mmol/l. Expression of the high affinity
glucose transporters (GLUT), GLUT1 and GLUT3 but not
of GLUT4, was found by Northern and Western analysis.
Similar to the findings with primary rat osteoblasts, but
distinct from those in rat fibroblasts, 2DG uptake and
glycogen synthesis were increased in this cell line after
exposure to low concentrations (0.1 nmol/l and above) of
PTH. IGF I at low doses (0.3 nmol/l and above) or insulin
at higher doses (1 nmol/l and above) stimulated 2DG
uptake and [3H] thymidine incorporation into DNA. 2DG
transport was enhanced already after 30 min of IGF I
treatment whereas the effect of PTH became significant
after 6 h. It is concluded that IGF I rather than insulin may
be a physiological regulator of 2DG transport and glycogen
synthesis in osteoblasts.
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Introduction
IGF I stimulates proliferation and differentiation of osteo-
blastic cells [1–3] whereas insulin has been considered the
physiological regulator of glucose metabolism in bone
cells. For example, insulin stimulates glucose uptake in rat
osteoblastic osteosarcoma cells [4, 5]. Besides insulin, also
PTH enhances glycogen synthesis in calvaria cells but not
in fibroblasts derived from newborn rats [6–8].
Cellular uptake of glucose is mediated by a family of
facilitative glucose transporter (GLUT) isoforms [9]. Three
of them are high-affinity transporters: GLUT1 (erythrocyte/
Hep G2) which is found in most tissues (including tumors)
and cell lines; GLUT3 (brain/placenta) which has the
highest affinity for glucose and which is particularly
abundant in brain (neurons); and GLUT4 (muscle/fat)
which is exclusively expressed in insulin-sensitive tissues
such as striated (skeletal and cardiac) muscle and adipose
tissue [10–17]. In bone cells, insulin stimulates the trans-
port of the glucose analogue 2-deoxy-D-glucose (2DG) [4],
but glucose transport could not be attributed to a specific
GLUT, although more recent findings indicate that both
GLUT1 and GLUT3 (mRNA and protein) are expressed in
rat osteogenic sarcoma cells [18]. GLUT3 was also
detected in bone, and it was suggested that insulin regulates
GLUT3-mediated glucose uptake in bone cells. Since
insulin receptors are abundant (*80,000/cell; [5]) in UMR
106-01 cells (University of Melbourne cell line, cloned
from 32P-induced rat osteogenic sarcoma), these have often
been used as a model to study insulin actions on the
osteoblast. IGF I mimics the stimulatory effect on glycogen
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synthesis from [14C] glucose in rat osteoblast-like cells
[1, 6] and is more potent than insulin in this respect. Since
the effects of insulin and IGF I on glucose transport have not
been directly compared in the same bone cell system, the
authors performed the current studies in osteoblastic PyMS
cells, a cell line derived from rat bone (not osteosarcoma).
Osteoblasts are typical target cells for calcium-regulating
hormones, PTH and vitamin D (its active form, 1a,25-
dihydroxyvitamin D3/1a,25-dihydroxycholecalciferol; sub-
sequently called vitamin D). Vitamin D and PTH share
inhibitory effects on alkaline phosphatase and citrate
decarboxylation in osteoblast-like cells [19], i.e., both may
affect the citrate cycle, but have distinct effects on cAMP
formation and phosphorylation patterns. The PyMS cell line
is not only responsive to IGF I and insulin but also to
vitamin D (increasing phosphate transport [20] and osteo-
pontin expression), prostaglandin E2 [21], PTH [22, this
report], and to an increase in extracellular calcium [23]. The
latter findings indicate that PyMS cells may be a valid bone
cell model to study hormonal effects on glucose metabo-
lism. PTH has been shown more than 50 years ago to affect
glucose handling by bone cells [24, 25]. The major portion
of glucose taken up by bone cells is metabolized to lactate
and CO2. PTH was found to increase lactate production and
to decrease citrate decarboxylation by bone and osteoblastic
cells [19, 24–27]. Moreover, it stimulated 2DG transport in
UMR 106-01 rat osteogenic sarcoma cells after 1 h, and
inhibited 2DG transport after 16 h [28]. PTH increased
[14C] glucose incorporation into glycogen in cultured rat
calvaria cells but not in fibroblasts [6].
The authors have compared the potencies of IGF I,
insulin, and PTH in stimulating 2DG uptake, the time
courses of this stimulation, and their effects on glycogen
synthesis in PyMS cells. It was found that GLUT1 and
GLUT3 mRNA, and GLUT1 and GLUT3 protein, but not
GLUT4 mRNA, were expressed in these osteoblastic cells,
and that IGF I stimulates 2DG uptake more potently than
insulin.
Materials and methods
Materials
Fetal calf serum (FCS), cell culture media, gentamicin,
glutamine, and trypsin were purchased from Life Tech-
nologies (Grand Island, NY, USA). Bovine serum albumin
was obtained from Serva and treated with charcoal;
recombinant human (rh) IGF I was obtained from Ciba-
Geigy, Basel; human insulin was gifted by Novo Nordisk.
Bovine parathyroid hormone (PTH, 1-34) was purchased
from Bachem, Torrence, CA.
Anti-glucose transporter 1 and 3 (GLUT1 and GLUT3)
antibodies were purchased from several companies: Alpha
Diagnostic (San Antonio, TX, USA), Biogenesis (Poole,
England, UK), Santa Cruz Biotechnology (Santa Cruz, CA,
USA), and FabGennix (Frisco, TX, USA) tested under a
variety of conditions, the latter appeared to be the most
useful in our hands.
Cell culture
Newborn rat calvaria cells and fibroblasts were prepared as
previously described [6, 29]. Both cell types were grown to
confluence on 10-cm-diameter plates in 5% FCS, detached
with trypsin and replated as described below for PyMS
cells. Secondary cultures were used. PyMS cells, a rat
osteoblastic cell line, were gifted by Dr. A. Lichtler, Uni-
versity of Connecticut. The cells were passaged in Falcon
tissue culture flasks in Dulbecco’s modified Eagle’s med-
ium (DMEM) supplemented with gentamicin (50 lg/ml),
glutamine (2 mmol/l), and fetal calf serum (5%) and kept
at 37C in an atmosphere of 5% CO2 in air. Cultures
between passages 13 and 35 were used.
PyMS cells grown to confluence were detached from the
dishes with 0.25% trypsin and replated in Falcon multiwell
tissue culture plates (35 mm diameter) at a density of
2 9 105 cells per well in DMEM medium containing 5%
FCS. Confluent monolayers formed 3 days after seeding.
Except for the experiments shown in Table 1 (6-h tests
carried out and stopped 3 days after plating), test incuba-
tions were stopped 4 days after seeding the cultures, as
shown in the flow diagram (Fig. 1). 24 h before take down,
cell cultures were rinsed with serum-free medium and then
kept in serum-free Ham’s F12 medium containing genta-
micin (50 lg/ml), glutamine (2 mmol/l) and charcoal-
treated bovine serum albumin (BSA, 1 g/l, from Serva).
Aliquots of test agents were added directly to the media.
Glucose transport studies
After culture (see above) and different treatments, mono-
layers were washed at room temperature with 1 ml transport
buffer containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl2,
1.5 mM CaCl2, 15 mM N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid (HEPES, adjusted to pH 7.4 with
Tris–HCl). Transport buffer containing choline chloride
instead of NaCl was used for measuring Na-independent
[1-14C] DG uptake. Uptake studies were initiated by adding
1 ml of transport buffer containing 0.1 mM cold DG and 2-
deoxy-D-[1-14C] glucose (1 lCi/ml; 58 mCi/mmol, Amer-
sham, UK). 10 min later (after 5, 10, and 20 min in the time
course experiments shown in Fig. 3), the buffer was
removed, and the dishes were quickly rinsed three times with
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1 ml of ice-cold transport buffer. The cells were then solu-
bilized with 1 ml of 2% sodium dodecyl sulfate (SDS), and
the radioactivity of a 0.5 ml aliquot was counted in a liquid
scintillation counter.
[U-14C] glucose incorporation into glycogen
After 3 days in culture (see above) in 5% FCS containing
DMEM, cell layers were washed with serum-free Ham’s F12
medium containing 1 g/l BSA and exposed for 6 h to IGF I or
PTH and 1 lCi/dish of D-[U-14C] glucose (Amersham,
270 mCi/mmol) in serum-free medium (Table 1). Alterna-
tively, cells cultured for 3 days as above were washed and
kept in serum-free medium for 24 h, and PTH, IGF I and
D-[U-14C] glucose were added for the times indicated in
Fig. 2 and Table 3. To measure net glycogen synthesis from
[14C] glucose, cells were washed with ice-cold phosphate-
buffered saline (PBS), and glycogen was precipitated and
14C counted in a b-counter as described [6, 29].
Determination of protein content
In order to correct for interassay differences in protein
content, identically treated dishes were used for protein
analysis. After 3 days (Table 1) or 4 days of culture (24 h
in serum-free medium), cells from parallel dishes were
lysed into 1 ml of 0.1% Triton X-100 for the determination
of protein content by a modification of the Lowry proce-
dure [20] or by the BCA method [22]; alkaline phosphatase
activity was also measured [20].
[3H] thymidine incorporation into DNA
Cells were plated and grown for 3 days in 5% FCS-
containing medium, then washed and exposed to serum-free
Table 1 Effects of IGF I and PTH on 2-deoxyglucose uptake and glycogen synthesis in rat fibroblasts, calvaria and PyMS cells
Cells-treatment (6 h) 2-Deoxyglucose uptake
(pmol/mg protein 9 10 min)
14C-glucose ? glycogen
(cpm/mg protein 9 6 h)
Fibroblasts
Control 2,157 ± 113 11,835 ± 301
IGF I, 10 nmol/l 3,110 ± 217* 26,345 ± 1,276*
PTH, 10 nmol/l 2,052 ± 161 12,774 ± 816
Calvaria cells
Control 1,368 ± 62 18,345 ± 2,065
IGF I, 10 nmol/l 1,965 ± 92* 41,523 ± 5,276*
PTH, 10 nmol/l 1,817 ± 156* 29,200 ± 2,716*
PyMS cells
Control 3,840 ± 186 13,442 ± 122
IGF I, 1 nmol/l 6,348 ± 172* 37,424 ± 1,792*
PTH, 10 nmol/l 4,457 ± 188* 16,041 ± 681
Cells were grown for 3 days in FCS-containing medium, rinsed and incubated for 6 h in serum-free medium with IGF I and PTH. Cells were
rinsed and switched to room temperature for measurement of deoxyglucose uptake or they were pulsed during the 6-h test period at 37C with
1 lCi D-[U-14C]-glucose. Incorporation into glycogen was measured as described in Materials and methods. Data from 3 separate experiments
(carried out in triplicate) are given
* P \ 0.05 for comparison of hormone-treated vs. control
Fig. 1 Flow diagram of treatment protocols. The experiments with
three distinct cell types summarized in Table 1 were performed
according to the three day protocol (A) while all other experiments
were performed only with PyMS cells, with a 4-day protocol (B)
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test medium (containing 1 g/l BSA and hormones as indi-
cated) for 18 h, and subsequently pulsed with [methyl-3H]
thymidine (Amersham, 80 Ci/mmol; 1 lCi/dish) for 3
additional h. After rinsing with cold PBS, DNA was pre-
cipitated and washed three times with 10% trichloroacetic
acid. The precipitate was dissolved in 1 N KOH, and
incorporated radioactivity was measured in a liquid scin-
tillation counter [20–23].
Total RNA isolation and Northern blot analysis
for GLUT1, GLUT3 and GLUT4 mRNA
Cells were plated at a density of 106 cells/10 cm diameter
dish (Falcon) in medium containing 5% FCS and grown for
3 days. Confluent monolayers were kept in serum-free
media for 24 h with hormones added as indicated. The
culture medium was sucked off and the cell layer was
washed 3 times with ice-cold PBS and scraped into ice-
cold PBS. Cells were collected and then lysed in 4 M
guanidine isothiocyanate containing 5 mmol/l sodium cit-
rate (pH 7.0), 0.1 M b-mercaptoethanol, and 0.5% sarco-
sine. Total RNA from rat osteoblast-like PyMS cells,
newborn rat calvarial bone, rat heart and rat brain was
obtained by high-speed sedimentation through a cesium
chloride cushion, and concentrations were determined
spectrophotometrically; RNA was stored at -80C until
assayed [30].
Denatured total RNA (20 lg) from tissues and cells was
electrophoresed on a 1% agarose gel (stained with ethidium
bromide) containing 2 M formaldehyde, transferred onto a
nylon membrane (Hybond-XL, Amersham, UK) by capil-
lary blotting, and fixed by UV cross-linking according to
standard procedures [31]. Prehybridization and hybridiza-
tion were performed as described earlier [32]. cDNA
probes of GLUT1 and GLUT3 were constructed using
RNA from rat tissues and RS-PCR, with the following set
of forward and reverse primers: 1A/1B (1A:50-GCGGGA
GAAGAAGGTC-30; 1B: 50-AGGAGAGTGGCTGATAA
AAA-30) for GLUT1 (GenBank accession no. M13979)
and U/L (U: 50-TGGAAGAGCGGTTGGA-30; L: 50-GGC
AGCGAAGATGATAAAAA-30) for GLUT3 (GenBank
accession no. U17978), corresponding to products of
1010 bp (GLUT1) and 1155 bp (GLUT3) on 1–1.5%
agarose gels. The cDNA probe for GLUT4 has been pre-
viously described [33]. The cDNA probes were labeled by
random primer extension using a commercial kit (Roche
Diagnostics) and [a-32P] deoxy-CTP (3,000 Ci/mmol;
Amersham) to specific activities of 2–4 9 109 cpm/lg
DNA. After 14–16 h of incubation at 42C, the membranes
were washed twice for 15 min at room temperature in
29 SSPE–0.1% SDS and then at 49–52C twice for 10 min
in 0.19 SSPE–0.1% SDS. Membranes were then exposed
at -80C to a BioMax film (Kodak, Rochester, NY, USA)
in cassettes equipped with intensifying screens to visualize
32P-labelled cDNA-mRNA hybrids. mRNA levels were
quantitated by scanning densitometry using a Bio-Rad
(Hercules, CA, USA) video densitometer. Variations of gel
loading were corrected against 18S ribosomal RNA levels.
Total membrane preparation and Western immunoblot
analysis for GLUT1 and GLUT3
Cells were plated at a density of 3 9 106 cells/15 cm
diameter dish (TPP) in medium containing 5% FCS and
grown for 3 days. Confluent monolayers were kept in
serum-free media for 24 h with hormones added as indi-
cated. Medium was removed, and the cell layers were
rinsed twice with ice-cold PBS; cells were scraped into
4 ml PBS and collected by centrifugation in a tube and the
pellet dissolved in 5 ml homogenization buffer (20 mM
HEPES, pH 7.4, 2 mM EDTA, 255 mM sucrose, and
containing 10 lg/ml aprotinin, 10 lg/ml leupeptin, and
200 lM PMSF as proteinase inhibitors), then glass Doun-
ce-homogenized by 15 moves/strokes, transferred back to
tubes and centrifuged for 10 min at 700 g and 4C; the
resulting supernatant was then centrifuged at 19,500 g for
75 min, and the pellet redissolved in 0.8 ml. An aliquot
was used for determination of the protein concentration by
the BCA method, and the tubes were frozen at -80C.
Thirty lg samples were mixed with loading buffer, heated
to 56C and applied per lane on SDS–PAGE (10%), and
transferred to a 0.2-lm nitrocellulose membrane (Trans-
Blot, BioRad 162-0147) for Western analysis. Equal
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Fig. 2 Effect of parathyroid hormone on D-[U-14C] glucose incorpo-
ration into glycogen in rat osteoblastic PyMS cells. Cells were grown
for 3 days in FCS-containing medium, rinsed with serum-free
medium and then exposed to serum-free medium for 24 h. PTH and
D-[U-14C] glucose were added for the last 6 h. Glycogen synthesis
was determined as described in Materials and methods (3 experi-
ments: 2 in triplicate and 1 in quadruplicate)
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loading was confirmed by Ponceau S staining. Filters were
incubated overnight at 4C in (affinity-purified) primary
antibody (rat Glut1 (FabGennix Inc; Glut-101 AP) and rat
Glut3 (FabGennix Inc; Glut-301 AP)), both at 1:4,000,
were then washed three times with TBS-T (Tris-buffered
saline-Tween-20) and incubated for 1 h in secondary
antibody (goat anti-rabbit HRP, BioRad 170-6515, at
1:3,000) at room temperature. After washing, proteins were
detected using the enhanced chemiluminescence (ECL)
detection reagents (Amersham 1059250) applied as rec-
ommended by the manufacturer (Amersham).
Statistical analysis
Results were obtained from 3 to 8 independent experi-
ments. Data are expressed as means ± SEM. Statistical
significance was assessed by one-way ANOVA with
repeated measures and Bonferroni’s multiple comparison
test correction using GraphPad Prism version 5.00 for
Windows (GraphPad Software, San Diego California
USA). A P value \0.05 was considered to be statistically
significant. Lineweaver–Burk trend lines were plotted with
double inverse value axes for uptake (y-axis) as function of
2DG concentrations (x-axis) and used for estimation of Km
and vmax.
Results
Characterization of PyMS cell responses to PTH
and IGF I
Preliminary experience with studies on glucose uptake in
PyMS cells and previous data on glycogen synthesis in rat
calvaria cells [6] had indicated that the treatment protocol
(serum withdrawal, medium change) had a marked influ-
ence on basal activities (glucose uptake and glycogen
synthesis) and hormone responsiveness; treatment proto-
cols are, therefore, outlined in Fig. 1. PTH-stimulated [14C]
glucose incorporation into glycogen (Fig. 2) in a dose-
dependent manner, significantly at 0.1 nmol/l and maxi-
mally at 10 nmol/l; the latter concentration was used for
the experiments shown in Tables 1, 2, 3. Vitamin D had no
effect (not shown) when tested under the same conditions.
The data summarized in Table 1 show 2DG uptake and
[14C] glucose incorporation into glycogen of PyMS cells,
as compared to rat fibroblasts and rat calvaria cells after 6-h
exposure to IGF I or PTH. IGF I exposure increased both
subsequent 2DG uptake and glycogen synthesis during the
test incubation in all cell types (a lower concentration of
IGF I was used in the case of PyMS cells since this cell line
is particularly sensitive to IGF I) [23]. PTH stimulated
2DG uptake and [14C] glucose incorporation into glycogen
only in calvaria and PyMS cells but not in fibroblasts, i.e.,
only in osteoblastic cells (Table 1). Only PyMS cells were
used for the following studies. Comparison of Fig. 2 and
Table 3 with Table 1 shows that PyMS cells incorporated
more glucose into glycogen when tested shortly after serum
deprivation than when kept under serum-free conditions
overnight before the 6-h test. On the other hand, PTH, was
relatively more effective in stimulating glycogen synthesis
under the latter conditions (serum-deprived for 18 h,
Fig. 2, Table 3) than immediately after serum deprivation
(Table 1).
Characterization of 2-deoxyglucose transport
2DG uptake was the same in sodium-containing and
sodium-free buffer, i.e., Na-independent. While previous
exposure to IGF I increased subsequent 2DG uptake by the
cells, replacing sodium by choline in the transport buffer
had no impact on 2DG uptake which increased linearly
with incubation time in control- and IGF I-treated cells for
at least up to 20 min (Fig. 3). Kinetic parameters of the
glucose transport system were obtained from Lineweaver–
Burk plots for which a series of experiments with 2DG
concentrations ranging from 0.02 to 2 mmol/l were carried
out. The apparent affinity constant (KM) of the glucose
transport was calculated from curves, and was similar in
PyMS (2.2 mmol/l) and calvaria cells (1.6 mmol/l) (mean
of 2 exp.); IGF I did not affect the KM of the transport
system but increased the maximal velocity (vmax) of the
glucose transport system when assessed in 6-h tests (as in
Tables 1 and 2).
Stimulation of 2DG transport by IGF I, insulin,
and PTH
IGF I was similarly effective in stimulating 2DG uptake
shortly following serum deprivation (Table 1) and after
being kept (for 18 h without hormones) in serum-free
medium (Tables 2 and 3). The stimulatory effect of
1 nmol/l IGF I on 2DG uptake was significant in cells
which had been exposed to IGF I for 30 min to 24 h
(Table 2). The (preexposure) effects of both IGF I and
insulin were more pronounced after 2 and 6 h than after
30 min, and their effects were compared by dose–response
curves. IGF I was effective at lower concentrations than
insulin (Fig. 4). Despite its pronounced effect on glycogen
synthesis (Fig. 2, Table 3), PTH was much less potent than
IGF I in stimulating 2DG uptake (Tables 1, 2, 3), a con-
sistent finding with the treatment protocol used in the
current experiments. Similar to previous findings in cal-
varia cells, PTH had no immediate (within the first 2 h)
stimulatory effect on 2DG uptake in PyMS cells; an
effect of PTH was observed only after a 6-h exposure
Mol Cell Biochem (2011) 348:33–42 37
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(Tables 1, 2, 3). Dose–response experiments revealed a
consistent and significant stimulatory effect of PTH on 2DG
uptake in 6-h tests (Fig. 4, treated/control P \ 0.01 for
all PTH concentrations versus control; conditions as in
Table 2, where the 6-h point shows only a 1.2-fold stimu-
lation), even at low doses (half-maximal stimulation at
*10 pmol/l), but the effect was minor, also at higher doses
of PTH (Table 1, Fig. 4), and much less impressive than its
effect on glycogen synthesis (Table 3, Fig. 2). PTH and IGF
I were also tested in combination. Their effects on glycogen
synthesis, but not on 2DG uptake, were additive (Table 3).
Effects of PTH, IGF I, and insulin on DNA synthesis
PTH caused a dose-dependent inhibition of [3H]thymidine
incorporation into DNA, significant at 1 nmol/l and above,
whereas vitamin D stimulated DNA synthesis in a dose-
dependent manner (significantly at 10 pmol/l and above) as
previously reported [20, 22]. Both IGF I and insulin
increased [3H]thymidine incorporation into DNA. IGF I
was effective at lower doses than insulin (Fig. 4).
GLUT1 and GLUT3 mRNA in rat bone
and osteoblastic cells
Total RNA was analyzed for GLUT-specific transcripts by
Northern blot hybridization. RNA was prepared from
PyMS cells and from newborn rat bone; for comparison,
RNA was prepared from newborn rat liver, brain, and heart
which served as positive controls for GLUT1, -3 and -4.
RNA from parietal bone (and from calvaria osteoblasts, not
shown) and from PyMS cells were positive for GLUT1
(mRNA size *3.0 kb) but gave a stronger signal with the
GLUT3 cDNA probe (mRNA size *4.0 kb) (Fig. 5, left),
and no signal at all with the GLUT4 probe (not shown,
heart and cultured heart muscle cells were positive for
GLUT4 [33]).
Table 2 Effects of IGF I and PTH on 2DG uptake (A) and protein content and alkaline phosphatase activity in PyMS cells: time course
Treatment 2-Deoxyglucose uptake (pmol/mg protein 9 10 min)
Time: 30 min 2 h 6 h 24 h
A
Control 704 ± 24 752 ± 46 652 ± 37 679 ± 57
IGF I, 1 nmol/l 914 ± 35* 1,295 ± 35* 1,228 ± 107* 919 ± 54*
PTH, 10 nmol/l 603 ± 42* 819 ± 57 760 ± 33 811 ± 63*
Treatment (24 h) Protein content (mg/dish) Alkaline phosphatase activity (lmol/h x mg protein)
B
Control 0.105 ± 0.003 3.36 ± 0.56
IGF I, 1 nmol/l 0.125 ± 0.007* 3.23 ± 0.45
PTH, 10 nmol/l 0.100 ± 0.002 3.68 ± 0.67
Cells were grown for 3 days in FCS-containing medium, rinsed with serum-free medium and kept in serum-free medium for the last 24 h. IGF I
(final concentration 1 nmol/l) and PTH (final concentration 10 nmol/l) were added for the indicated times before assessment of 2DG uptake (A)
and determination of protein content and alkaline phosphatase activity (B) per dish, as described in Materials and methods. Data from 3 separate
experiments (carried out in triplicate) are shown
* P \ 0.05 for comparison of hormone-treated vs. control
Table 3 Effects of IGF I and PTH on 2DG uptake and glycogen synthesis in PyMS cells
Treatment (6 h) 2-Deoxyglucose uptake (pmol/mg protein 9 10 min) 14C-glucose ? glycogen (cpm/mg protein 9 6 h)
Control 773 ± 88 280 ± 40
PTH, 10 nmol/l 930 ± 90 1,044 ± 61*
IGF I, 1 nmol/l 1,781 ± 164* 870 ± 40*
IGF I ? PTH 1,588 ± 178* 2,203 ± 157**
Cells were grown for 3 days in FCS-containing medium and kept in serum-free medium for the following (last) 24 h. IGF I (final concentration
1 nmol/l) or PTH (final concentration 10 nmol/l) were added 6 h before assessment of 2DG uptake or of glycogen synthesis from D-[U-14C]
glucose. Data from 3 separate experiments (carried out in triplicate) are shown
* P \ 0.05 for comparison of hormone-treated vs. control
** P \ 0.05 for comparison of IGF I- ? PTH-treated vs. IGF I- or PTH-treated alone
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GLUT1 and GLUT3 in rat osteoblastic cells
Total membranes were analyzed for GLUT1, and GLUT3
protein by Western blot analysis (the authors had tried a
variety of commercially available antibodies, and finally
found the ones given in the Materials and methods section
to be the most suitable); for comparison, total membranes
were prepared from rat brain which served as positive
control for GLUT1 and GLUT3 (Fig. 5, right). The stron-
gest signals with GLUT1 and GLUT3 antibodies were
found in membranes prepared from brain (at *44 and at
*45–48 kDa), and bands were also detected in membranes
prepared from PyMS cells, at apparent molecular masses of
*48–50 kDa for GLUT1 and of *45–49 kDa for GLUT3.
The small observed differences in the MW could be
attributed to tissue-specific differences (between brain
and bone cells) in the glycosylation patterns of the
proteins [34].
Discussion
Insulin deficiency causes severe metabolic disturbances
and diabetic bone disease [35, 36]. The latter may be due
not only to indirect effects but also to insulin deficiency per
se. Insulin increases collagen synthesis [37] and bone for-
mation [38]. Insulin resistance and hyperinsulinemia are
associated with increased bone mineral density; this posi-
tive association, however, has been found to be diminished
after adjustment for body mass index [39]. Insulin recep-
tors are present in UMR-106 rat osteoblastic osteosarcoma
cells [4, 5, 40] and in rat bone [41] and therefore, it has
been suggested that insulin may stimulate glucose uptake
also in bone [42]. However, the reported insulin dose–
response curves for 2DG uptake are distinct from those
observed in fat cells, where insulin stimulates GLUT4-
mediated glucose transport. Thus, previous studies reported
an ED50 of 9 9 10
-10 mol/l [5] or of *10-8 mol/l [41] for
insulin-stimulated glucose uptake in osteosarcoma cells (as
compared to *5 9 10-11 mol/l in adipocytes). Few stud-
ies have tested the effects of insulin on glucose transport in
isolated non-malignant osteoblast-like cells, but IGF I has
not been tested. The authors had previously found that IGF
I was effective at lower concentrations than insulin in
stimulating glycogen synthesis from [14C] glucose in
PyMS and primary rat calvaria cells [1, 6, 29]. Our current
studies show that IGF I stimulates glucose transport in
PyMS cells and that it is effective at much lower concen-
trations than insulin, not only regarding glycogen and DNA
synthesis but also with regard to enhancing glucose uptake
(Fig. 4): 10–20 times higher concentrations of insulin than
of IGF I are required for significant stimulation of DNA
synthesis and 2DG uptake; even 50–100 times higher
concentrations of insulin than of IGF I are needed for half
maximal stimulation of DNA synthesis and 2DG uptake.
Since insulin binds type 1 IGF receptors with a Kd of
*10-8 mol/l, whereas it binds to its own receptors with a
much lower Kd (*10
-10 mol/l), it is likely that insulin
signals through type 1 IGF receptors to stimulate glucose
uptake in osteoblastic, at least in PyMS cells. These cells
are particularly sensitive to stimulation by IGF I since they
have a high number of type 1 IGF receptors and since they
do not produce significant amounts of IGF I [23].
According to our findings, the ‘‘insulin-sensitive’’ glucose
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Fig. 3 Effects of different incubation times (for the uptake assay),
sodium-containing and sodium-free (choline-containing) transport
buffer on 2DG uptake in osteoblastic cells exposed to hormone-free
control medium or to IGF I for the last 6 h. Cells were grown for
3 days in FCS-containing medium, rinsed with serum-free medium
and then exposed to serum-free medium for 24 h. IGF I (final
concentration 1 nmol/l) was added for the last 6 h before assessment
of 2DG uptake which was measured over different times in sodium-
containing (left) and in sodium-free (choline-containing, right) buffer,
as described in Materials and methods. Data from 2 separate
experiments (carried out in triplicate) are shown
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uptake system in osteoblastic cells may be rather an IGF I-
sensitive glucose uptake system, and type 1 IGF receptors
are likely to play a major role in mediating 2DG uptake by
rat PyMS cells. It may be argued that PyMS cells represent
a ‘‘preosteoblastic’’ cell line [20] and that the role of insulin
may be more prominent in osteoblasts. Insulin was more
effective with regard to stimulation of collagen synthesis in
rat osteosarcoma UMR cell lines [40] than in ‘‘non-trans-
formed’’ preosteoblastic UMR cell lines [43]; however,
even in the former cells, 1 nmol/l of insulin was required to
exert a significant effect. The authors have directly com-
pared the potencies of insulin and IGF I and found that
IGF I was effective at lower doses than insulin, in primary
rat osteoblasts [29] and in PyMS cells, both regarding 2DG
uptake (Fig. 4) and glycogen synthesis [1]. Glucose uptake
by rat osteoblastic cells is a Na-independent process. By
contrast, phosphate and alanine uptake in the same cell line
are Na-dependent processes [20, 21, 23]. The apparent KM
for 2DG uptake in both primary rat calvaria and PyMS
cells was *1.6 and *2.2 mmol/l, respectively, i.e., close
to the published KM of the high affinity glucose transporters,
particularly GLUT3 [44]. For the latter, the KM for 2DG was
found to be lowest, i.e., at 1–2 mmol/l when tested in
Xenopus oocyte expression system [44]. A similar KM value
for the 2DG transport system has been reported for UMR
osteosarcoma cells (1.9 mmol/l) [4]. KM values for the high
affinity GLUTs vary according to the literature, being lowest
for GLUT3 (1.4 mmol/l) and somewhat higher for GLUT1
(6.9 mmol/l) [16]. Our analysis with osteoblastic cells sug-
gests a dominant role of high affinity glucose transporters
but cannot give an accurate figure since it is likely that
several GLUTs account for overall glucose uptake by the
cells. Thomas and co-workers [28] found a stimulatory
effect of PTH on 2DG uptake in UMR cells at 1 h (and
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Fig. 4 Effects of PTH, IGF I, and insulin on 2DG uptake and DNA
synthesis in rat osteoblastic cells. 2-deoxyglucose uptake (upper
panels) and [3H] thymidine incorporation into DNA (lower panels) in
PyMS cells exposed to PTH (left panels) or to IGF I and insulin (right
panels). Cells were grown for 3 days in FCS-containing medium,
rinsed with serum-free medium, and exposed for 24 h to serum-free
medium. PTH was added for the last 6 h; IGF I or insulin were added
for the last 2 h. 2DG uptake was then measured at room temperature
as described in Materials and methods (2DG uptake PTH (6 h): 8
experiments in triplicate; 2DG uptake IGF I/insulin (2 h): 6 exper-
iments in triplicate), or exposed to serum-free test medium containing
PTH, IGF I or insulin for 18 h and pulsed with 1 lCi [methyl-3H]
thymidine for additional 3 h (thymidine incorporation PTH: 5
experiments in triplicate; thymidine incorporation IGF I/insulin: 3
experiments in triplicate)
Fig. 5 Northern blot (left panel) and Western immunoblot (right
panel) analysis for GLUT1 and GLUT3. Northern blot analysis for
GLUT1 and GLUT3: Total RNA was prepared from rat brain and
bone, and from PyMS cells (treated for the last 6 h with control or
IGF I-containing test medium) and subjected to Northern. Twenty lg
RNA was loaded per lane. Bars indicate the position of ribosomal
RNA. GLUT1 and GLUT3 mRNA are particularly abundant in brain
but also detectable in bone and in PyMS cells. Western immunoblot
analysis for GLUT1 and GLUT3: Total membranes were prepared
form rat brain and from PyMS cells (treated for the last 6 h with
control or IGF I-containing test medium) and subjected to Western.
Thirty lg protein was loaded per lane; bars indicate the position of
marker proteins. GLUT proteins were less abundant in TM from
PyMS cells than in TM from brain. GLUT1 is detected at an apparent
molecular weight of about 50 kDa, GLUT3 at an apparent molecular
weight of about 45–47 kDa
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inhibition at 16 h). The authors found stimulatory effects of
PTH on 2DG uptake after 6 and 24 h in the PyMS cells
(Table 2), as well as an identical time course in primary
calvaria cells. DNA synthesis is clearly decreased by PTH,
as a consequence, glucose will not be increasingly used for
growth in response to PTH stimulation. Therefore, unlike
the stimulatory effect of IGF I, the effect of PTH on 2DG
uptake and on glycogen synthesis may be relatively specific
as it is restricted to osteoblastic cells (Table 1) and as it is not
readily explained in the context of overall stimulation of cell
proliferation.
Previous studies [18] indicated that rat osteogenic
osteosarcoma cells express both GLUT1 and GLUT3. They
found GLUT3 mRNA and protein in several UMR rat
osteoblastic cell lines and GLUT3 mRNA in rat bone,
suggesting that GLUT3 is expressed in osteoblastic cells.
Our observations with a different (non-tumorigenic) cell
line support this finding. The hybridization signal of
GLUT3 transcripts is also present in rat bone and in rat
calvaria cells (not shown). In agreement with findings in
mammalian neuroblasts and trophoblasts, GLUT1, the
isoform that is ubiquitously found in all proliferating cells,
is replaced by GLUT3 when PyMS cells decrease their
growth rate and begin differentiating to attain their mature
functional form. Glucose uptake was the highest in serum-
primed cells, i.e., when the cells were rapidly growing, and
GLUT1 mRNA expression was relatively high; it is also
known that GLUT1 is expressed at high levels by most
tumor cells and may, therefore, serve to cover the particular
requirement for rapid growth (allowing tumor visualization
in vivo by 2-deoxy-2-[18F]fluoro-D-glucose positron emis-
sion tomography [45]). GLUT1 mRNA was downregulated
when PyMS cells were kept for a prolonged period of time
in serum-free medium. Results from our laboratory (in
preparation) have shown that under these conditions, (IGF I
responsiveness is maintained and PTH responsiveness
markedly increased, with a 3.4 ± 0.2-fold stimulation of
2DG uptake) overall (presumably ‘‘growth-related’’) 2DG
uptake decreased, as also indicated by comparing 2DG
uptake rates in Tables 1, 2, and 3, illustrating the effect of
short-term serum deprivation. To avoid different degrees of
residual serum effects, the time course experiments pre-
sented in Table 2 share a common culture period including
the same time in serum-free medium. In contrast to tissues
with insulin-regulated glucose uptake (adipose tissue, stri-
ated muscle), GLUT4 mRNA could not be detected in
PyMS cells, primary calvaria-derived osteoblasts, or pari-
etal bone. It cannot be ignored that additional members of
the SLC2 family (GLUT6 to GLUT14) may be involved in
the glucose uptake in PyMS cells, since several of these
newer members of GLUTs are bona fide glucose trans-
porters [46]. Thus far, it has not been possible to assign
glucose transport in osteoblasts to a specific GLUT isoform,
but the findings of this study suggest that GLUT3 and
GLUT1 remain the best candidates. GLUT3 and GLUT1
could be identified in PyMS cells and high affinity glucose
transport would be consistent with GLUT3 playing a central
role. IGF I rapidly increases 2DG uptake, well before
marked changes in GLUT protein synthesis and cellular
content occur, consistent with translocation of GLUTs from
an intracellular membrane fraction to the plasma mem-
brane. GLUT1 and GLUT4 facilitative glucose transporters
translocate in response to IGF I or insulin stimulation [47],
and GLUT3 is also redistributed in response to IGF I or
insulin after short-term exposure, e.g., in L6 rat myotubes
[48]. However, there is currently no proof to establish that
the observed increased 2DG uptake by osteoblastic cells in
response to acute IGF I stimulation can be attributed to a
translocation of GLUT3 (or GLUT1)-containing vesicles
from an intracytoplasmic pool to the plasma membrane.
According to our findings, GLUT4 is absent in osteoblastic
cells, and insulin is unlikely to play a physiological role in
stimulating glucose transport in bone tissue.
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